ArticleCancer cytopathology2026
Exploring alternatives to tumor tissue for BRCA1/2 next-generation sequencing testing in high-grade serous ovarian cancer: A 34-case series of malignant ascites.
Article in Cancer cytopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBRCA1/2 testing is currently recommended at diagnosis for high-grade serous ovarian carcinoma (HGSOC) because of its impact on patients' survival when treated with poly(adenosine diphosphate ribose) polymerase inhibitors. Standard clinical practice involves analyzing BRCA1/2 genes in formalin-fixed, paraffin-embedded (FFPE) histological specimens. However, because neoplastic ascites is a common clinical presentation in HGSOC and provides a good source of neoplastic cells via a less invasive procedure, it is worthwhile to explore the feasibility of BRCA1/2 testing on cytological specimens obtained from malignant ascites.
methodsBRCA1/2 status was analyzed in 34 ascites-derived cytological samples via an amplicon-based next-generation sequencing (NGS) approach, and the results were compared with those from FFPE tissues previously tested in routine clinical practice.
resultsA perfect match was observed between BRCA1/2 testing results from neoplastic ascites and surgical samples (100% concordance) for all pathogenic variants, including both germline and somatic mutations. This is the first study to report such high concordance within the largest collection of somatic variants analyzed to date. Additionally, molecular NGS testing was demonstrated to be feasible even in malignant ascites with a low tumor fraction and with archived material.
conclusionsThis study shows that ascites can be a suitable specimen for BRCA1/2 NGS testing, and provides a minimally invasive option for disease diagnosis and the early detection of key molecular biomarkers essential for the clinical management of women with HGSOC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.